GlaxoSmithKline nabs EU nod for Relvar in asthma; Elan shareholders give final blessing to Perrigo buyout;

GSK HQ

@FiercePharma: The weekend's best-read special report: Top Pharma Companies by 2012 Revenues. Read | Follow @FiercePharma

@EricPFierce: Pfizer gives BlackBerry the raspberry. Piece | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from biotech products. Report | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) and its partner Theravance ($THRX) said their respiratory drug Relvar Ellipta won approval as an asthma treatment in Europe; it's approved under the brand name Breo Ellipta in the U.S. to treat COPD. Release

> Ireland-based Elan ($ELN) won approval from shareholders to sell itself to the U.S. drugmaker Perrigo ($PRGO). Report

> Valeant Pharmaceuticals ($VRX) priced a $900 million debt offering to be used to pay down debt associated with recent acquisitions. Report

> The Danish drugmaker LEO Pharma signed on to market Antares Pharma's ($ATRS) psoriasis treatment Otrexup in the U.S. Report

> Akorn ($AKRX) bought the rights to three Merck ($MRK) eye-drop brands, including the glaucoma treatment Cosopt, for $52.8 million. Report

Medical Device News

@FierceMedDev: TriVascular lands $40M round for aortic stent grafts. Story | Follow @FierceMedDev

@MarkHFierce: Medtronic's latest earnings report comes out on Nov. 19. | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Brain tumors succumb to drugs delivered via bone scaffold. More | Follow @MichaelGFierce

> Medtronic guidewires draw Class I recall due to deadly risk. Article

> CareFusion scoops up GE Healthcare Vital Signs arm for $500M. News

> Varian Medical eyes repurchase of 6 million more shares through 2014. Item

Biotech News

@FierceBiotech: Tufts: Big Pharma bets its future on a swelling pipeline of biologic. Article | Follow @FierceBiotech

@JohnCFierce: AbbVie scores SVRs of 95% and 98% for GT1a and GT1b groups in first PhIII hep C study. More | Follow @JohnCFierce

@DamianFierce: FierceBiotech, coming soon to an Android near you. (Get your iPhone/iPad version in the iTunes store.) Download | Follow @DamianFierce

@EmilyMFierce: Federal government to transfer laboratory chimps to sanctuaries. Story | Follow @EmilyMFierce

> Big Pharma venture teams back Aileron's shift to early-stage R&D. Article

> Pfizer joins Roche, GSK in $32M round for Mission Therapeutics. More

> In another big cancer setback, Sanofi shutters fedratinib program. News

CRO News

> Post-merger PRA makes another buy, grabbing CRI Lifetree. More

> WuXi boosts outlook as Chinese CRO market swells. Story

> Icon rolls out data visualization tech for adaptive trials. News

> Quintiles expands trial monitoring to slash study costs. Article

> Report: Medpace up for $1.2B sale as CRO M&A heats up. Report

> Catalent cuts ribbon on Chinese trial-supply facility. Item

Biotech IT News

> Falling cost of next-gen sequencing to drive informatics boom. News

> Pfizer takes steps to protect itself from BlackBerry's woes. More

> Validic raises cash to turn mHealth app output into data hose. Piece

> Pfizer finally takes control of Twitter account. Item

> EMA warns of possible delay to final trial data transparency policy. Article

And Finally... Childhood cancer survivors should take measures as soon as possible after treatment to reduce their risks of cardiovascular complications later in life. Report